Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1166-1170. doi: 10.19723/j.issn.1671-167X.2020.06.032

Previous Articles    

Progress in interferon: A treatment of Behcet syndrome

Dong YAN1,Wen-jie ZHENG2,△()   

  1. 1. Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu,China
    2. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China
  • Received:2020-07-10 Online:2020-12-18 Published:2020-12-13
  • Contact: Wen-jie ZHENG E-mail:zhengwj@pumch.cn

RICH HTML

   

PDF (PC)

Abstract:

Behcet syndrome (BS) is a chronic systemic inflammatory disorder involving vessels of all sizes, characterized by relapsing episodes of oral and/or genital ulcers, as well as skin lesions. Ocular, vascular, gastrointestinal, neurological system involvement can cause significant morbidity and mortality. Glucocorticoids and immunosuppressants are the cornerstones for the management of BS. Biologic agents has been recommended for severe and/or refractory BS. Interferon-α (IFN-α) had multiple biological effects, such as antiviral and antiproliferative, that could regulate both innate and adaptive immunity in BS. Growing evidence showed the efficacy of IFN-α in severe and/or refractory BS. Many studies have demonstrated that IFN-α has comparable effectiveness and tolerance profiles as anti-tumor necrosis factor (TNF) agents for Behcet’s uveitis with a much lower cost and steroid-and immunosuppressant-sparing effects. IFN-α has been recommended as second-line therapy for ocular involvement of BS in EULAR (The European League Against Rheumatism) 2018. IFN-α also improves mucocutaneous lesions in BS with the dosage from 3 to 9-12 million IU three times per week. A few cases indicated the therapeutic potential of IFN-α in intestinal BS. As a new trial of IFN-α in vascular BS (VBS), a recent study revealed the lower relapse rate and higher recanalization rate with IFN-α in lower extremity deep vein thrombosis (DVT). Another two case reports presented the efficacy of IFN-α in pulmonary artery involvement in BS. Also, case reports have shown successful treatment in refractory neurological involvement. There are two subtypes of IFN-α commonly used in autoimmune diseases, named IFN-α2a and IFN-α2b. IFN-α2a seemed more effective than IFN-α2b, especially in ocular and mucocutaneous involvement of BS. Side effects of IFN-α are dose-dependent and not severe. The most frequent side effects are flu-like syndrome, mild leukopenia and alopecia. Considering the potential risk of tuberculosis (TB) and hepatitis B virus (HBV) reactivation of TNF-α inhibitors, IFN-α is safe due to its anti-HBV effect and protective effect on TB. In conclusion, IFN-α is a promising choice for severe and/or refractory BS patients, especially for those who are intolerant or contraindicant to other biological agents, such as TNF inhibitors. Further prospective controlled studies are warranted to confirm the efficacy and safety of IFN-α in BS.

Key words: Behcet syndrome, Biological agents, Interferon-α

CLC Number: 

  • R597
[1] Ozguler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations[J]. Rheumatology (Oxford), 2018,57(12):2200-2212.
doi: 10.1093/rheumatology/key242
[2] 严冬, 赵岩, 曾小峰, 等. 生物制剂治疗重症和(或)难治性神经白塞病临床分析[J]. 中华风湿病学杂志, 2018,22(3):148-153.
[3] Ding Y, Li C, Liu J, et al. Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet’s disease: a single-centre experience in China[J]. Rheumatology (Oxford), 2018,57(11):2057-2059.
[4] Barešić M, Reihl M, Habek M, et al. Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab[J]. Rheumatol Int, 2018,38(7):1301-1306.
doi: 10.1007/s00296-018-4054-9 pmid: 29777341
[5] Ayaz C, Celen MK, Colak H, et al. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B[J]. Indian J Gastroenterol, 2006,25(2):71-73.
pmid: 16763334
[6] Aruna, Li L. anti-interferon alpha antibodies in patients with high-risk BCR/ABL-negative myeloproliferative neoplasms treated with recombinant human interferon-α[J]. Med Sci Monit, 2018,24:2302-2309.
doi: 10.12659/MSM.907876 pmid: 29693647
[7] Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions[J]. Annu Rev Biochem, 1987,56:727-777.
doi: 10.1146/annurev.bi.56.070187.003455 pmid: 2441659
[8] Tsambaos D, Eichelberg D, Goos M. Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon[J]. Arch Dermatol Res, 1986,278(4):335-336.
doi: 10.1007/BF00407749 pmid: 3740944
[9] Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome[J]. Ann Rheum Dis, 2018,77(6):808-818.
doi: 10.1136/annrheumdis-2018-213225 pmid: 29625968
[10] Theofilopoulos AN, Baccala R, Beutler B, et al. Type Ⅰ inter-ferons (alpha/beta) in immunity and autoimmunity[J]. Annu Rev Immunol, 2005,23:307-336.
doi: 10.1146/annurev.immunol.23.021704.115843 pmid: 15771573
[11] Snell LM, McGaha TL, Brooks DG. Type Ⅰ interferon in chronic virus infection and cancer[J]. Trends Immunol, 2017,38(8):542-557.
doi: 10.1016/j.it.2017.05.005 pmid: 28579323
[12] Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17-inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet’s disease[J]. Immunol Invest, 2017,46(5):518-525.
doi: 10.1080/08820139.2017.1306865 pmid: 28414558
[13] Ekinci NS, Alpsoy E, Karakas AA, et al. IL-17A has an important role in the acute attacks of Behçet’s disease[J]. J Invest Dermatol, 2010,130(8):2136-2138.
doi: 10.1038/jid.2010.114 pmid: 20445554
[14] Hamzaoui K, Hamzaoui A, Hentati F, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behçet’s disease[J]. J Rheumatol, 1994,21(12):2301-2306.
pmid: 7699633
[15] Albayrak O, Oray M, Can F, et al. Effect of Interferon alfa-2a treatment on adaptive and innate immune systems in patients with Behçet disease uveitis[J]. Invest Ophthalmol Vis Sci, 2019,60(1):52-63.
doi: 10.1167/iovs.18-25548 pmid: 30601931
[16] Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease[J]. Rheumatology (Oxford), 2011,50(2):293-298.
doi: 10.1093/rheumatology/keq330
[17] Touzot M, Cacoub P, Bodaghi B, et al. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease[J]. Autoimmun Rev, 2015,14(5):370-375.
pmid: 25541082
[18] Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells[J]. Nat Rev Immunol, 2010,10(3):170-181.
doi: 10.1038/nri2711 pmid: 20154735
[19] Pirhonen J, Sirén J, Julkunen I, et al. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages[J]. J Leukoc Biol, 2007,82(5):1185-1192.
doi: 10.1189/jlb.0307157 pmid: 17684041
[20] Metzger R, Heckl-Ostreicher B, Nerl C, et al. Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo[J]. Leuk Res, 1992,16(11):1087-1095.
doi: 10.1016/0145-2126(92)90047-b pmid: 1434745
[21] Eguchi K, Kawakami A, Nakashima M, et al. Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells[J]. Clin Exp Immunol, 1992,88(3):448-454.
doi: 10.1111/j.1365-2249.1992.tb06470.x pmid: 1606729
[22] Koie T, Suzuki K, Shimoyama T, et al. Effect of interferon-alpha on production of reactive oxygen species by human neutrophils[J]. Luminescence, 2001,16(1):39-43.
doi: 10.1002/bio.606 pmid: 11180657
[23] Kötter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature[J]. Semin Arthritis Rheum, 2004,33(5):320-335.
doi: 10.1016/j.semarthrit.2003.09.010 pmid: 15079763
[24] Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection[J]. Clin Ther, 2002,24(9):1363-1383.
doi: 10.1016/S0149-2918(02)80042-X
[25] Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients[J]. Am J Ophthalmol, 2004,138(3):373-380.
pmid: 15364218
[26] Kötter I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study[J]. Br J Ophthalmol, 1998,82(5):488-494.
doi: 10.1136/bjo.82.5.488 pmid: 9713053
[27] Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis[J]. Arch Ophthalmol, 2011,129(3):288-294.
doi: 10.1001/archophthalmol.2011.3 pmid: 21402983
[28] Eser-Ozturk H, Sullu Y. The results of interferon-alpha treatment in Behçet uveitis[J]. Ocul Immunol Inflamm, 2020,28(3):498-504.
doi: 10.1080/09273948.2019.1587473 pmid: 31161949
[29] Shi J, Zhao C, Zhou J, et al. Effectiveness and safety of inter-feron α2a as an add-on treatment for refractory Behçet’s uveitis[J]. Ther Adv Chronic Dis, 2019,10:1-9.
[30] Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study[J]. Clin Rheumatol, 2017,36(1):183-189.
doi: 10.1007/s10067-016-3480-x pmid: 27853889
[31] Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study[J]. Ophthalmology, 2014,121(10):1877-1884.
doi: 10.1016/j.ophtha.2014.04.042
[32] Yalçindag N, Köse HC. Comparison of the treatment results for behçet’s uveitis in patients treated with infliximab and interferon[J]. Ocul Immunol Inflamm, 2020,28(2):305-314.
pmid: 31268743
[33] Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome[J]. Semin Arthritis Rheum, 2019,48(4):752-762.
pmid: 29954598
[34] Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial[J]. Semin Arthritis Rheum, 2004,33(5):311-319.
doi: 10.1016/j.semarthrit.2003.09.005 pmid: 15079762
[35] Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study[J]. Arch Dermatol, 2002,138(4):467-471.
doi: 10.1001/archderm.138.4.467 pmid: 11939808
[36] Esatoglu SN, Hatemi G. Update on the treatment of Behçet’s syndrome[J]. Intern Emerg Med, 2019,14(5):661-675.
doi: 10.1007/s11739-019-02035-1 pmid: 30684097
[37] Grimbacher B, Wenger B, Deibert P, et al. Loss of vision and diarrhoea[J]. Lancet, 1997,350(9094):1818.
doi: 10.1016/s0140-6736(97)10114-3 pmid: 9428254
[38] Monastirli A, Chroni E, Georgiou S, et al. Interferon-α treatment for acute myelitis and intestinal involvement in severe Behçet’s disease[J]. QJM, 2010,103(10):787-790.
doi: 10.1093/qjmed/hcq125 pmid: 20650970
[39] Demir S, Sag E, Kaya Akca U, et al. The challenge of treating pulmonary vasculitis in Behçet disease: two pediatric cases[J]. Pediatrics, 2019,144(2):162.
[40] Ozguler Y, Hatemi G, Cetinkaya F, et al. Clinical course of acute deep vein thrombosis of the legs in Behçet’s syndrome[J]. Rheumatology (Oxford), 2020,59(4):799-806.
doi: 10.1093/rheumatology/kez352
[41] Yan D, Liu J, Zhang Y, et al. The Clinical features and risk factors of parenchymal neuro-Behcet’s disease[J/OL]. J Immunol Res, 2019, 2019: 7371458[2020-07-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757281/.
[42] Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of neuro-Behçet’s disease: international consensus recommendations[J]. J Neurol, 2014,261(9):1662-1676.
doi: 10.1007/s00415-013-7209-3 pmid: 24366648
[43] Chroni E, Monastirli A, Polychronopoulos P, et al. Epileptic seizures as the sole manifestation of neuro-Behçet’s disease: complete control under interferon-alpha treatment[J]. Seizure, 2008,17(8):744-747.
doi: 10.1016/j.seizure.2008.05.008 pmid: 18562217
[44] Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha: a new therapeutic option in refractory juvenile Behçet’s disease with CNS involvement[J]. Rheumatology (Oxford), 2008,47(7):1051-1053.
doi: 10.1093/rheumatology/ken172
[45] Nichols JC, Ince A, Akduman L, et al. Interferon-alpha 2a treatment of neuro-Behcet disease[J]. J Neuroophthalmol, 2001,21(2):109-111.
doi: 10.1097/00041327-200106000-00011 pmid: 11450899
[46] Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders[J]. Clin Immunol Immunopathol, 1992,65(1):70-74.
doi: 10.1016/0090-1229(92)90250-r pmid: 1382910
[47] Keskin Y, Seyahi E, Poyraz C, et al. Interferon alfa-associated depression in patients with Behçet’s syndrome: a prospective controlled study[J]. Clin Exp Rheumatol, 2014,32(4 Suppl 84):S175.
pmid: 25268670
[48] 王宇. 全国第五次结核病流行病学抽样调查资料汇编 [M]. 北京: 军事医学科学出版社, 2011: 17.
[49] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018,3(6):383-403.
doi: 10.1016/S2468-1253(18)30056-6 pmid: 29599078
[50] Kisacik B, Pamuk ON, Onat AM, et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence[J]. J Rheumatol, 2016,43(3):524-529.
doi: 10.3899/jrheum.150177 pmid: 26773107
[51] Chyuan IT, Hsu PN. Tumor necrosis factor: the key to hepatitis B viral clearance[J]. Cell Mol Immunol, 2018,15(8):731-733.
doi: 10.1038/cmi.2017.139 pmid: 29375133
[52] Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy[J]. J Am Acad Dermatol, 2009,60(6):1001-1017.
doi: 10.1016/j.jaad.2008.12.031 pmid: 19344980
[53] Lande R, Giacomini E, Grassi T, et al. IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells[J]. J Immunol, 2003,170(3):1174-1182.
pmid: 12538673
[1] Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56dimCD57+natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[2] Chen YU,Chun LI,Yang-yi FAN,Yan XU. Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1146-1149.
[3] Lu-xi SUN,Jin-jing LIU,Yun-xia HOU,Chao-ran LI,Lu LI,Xin-ping TIAN,Xiao-feng ZENG,Wen-jie ZHENG. Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1056-1062.
[4] WANG Yu, YANG Liu, ZHANG Zhuo-li. Panuveitis with oral and genital ulcer misdiagnosed as Behcet’s disease: two cases report and literature review [J]. Journal of Peking University(Health Sciences), 2016, 48(5): 910-913.
[5] HUANG Qing, WANG Xue-mei, LIU Yu-lan, FENG Gui-jian, YOU Peng.  Capsule endoscopy for Behcet’s disease-treatment: five cases reports [J]. Journal of Peking University(Health Sciences), 2016, 48(2): 366-369.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd